Crescita Therapeutics(TM) Inc. Announces Acquisition of INTEGA Skin Sciences

About this update from Crescita Therapeutics, Inc.

[{"type":"text","content":"\n\n\n\nCrescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCrescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences\nCanada NewsWire\nMISSISSAUGA, ON, Sept. 1, 2016\n\n\n\n- Crescita Becomes An Integrated and Growing Commercial Skin Care Business - \n\n\n\nMISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Crescita Therapeutics Inc. (TSX:CTX) (Crescita or the Company), a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc. (INTEGA), a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products.  INTEGA, financially backed by Knight Therapeutics (TSX:GUD) and Bloom Burton Healthcare Lending Trust, owns the Canadian distribution rights for a number of well-known and established skin care brands, including Laboratoire Dr. Renaud. \n\nKey Benefits of the Transaction:\n\n\nProvides Crescita with a revenue-generating, fully integrated commercial skin care business, manufacturing facilities, and the capability to market prescription and over-the-counter (OTC) skin care products through established distribution channels; \nProvides Crescita with distribution rights to well-known and established skin care brands: Laboratoire Dr Renaud, Pro-Derm, Premiology and ISDIN; \nProvides Crescita with a commercial infrastructure capable of promoting its prescription drug Pliaglis in Canada; \nAllows Crescita to leverage its topical delivery technologies for the development of potential new OTC and/or prescription skin care products; \nAllows Crescita to leverage its business development capabilities to out-license INTEGA owned brands outside Canada, including the U.S; and \nSignificant cash on hand in order to make additional acquisitions.\n\n\"With the acquisition of INTEGA, paid in Crescita common shares valued at $2.44 per share, Crescita becomes an inte...

More updates from Crescita Therapeutics, Inc.